Absorption, Distribution, Metabolism, and Excretion of FDA-approved Antisense Oligonucleotide Drugs

被引:18
|
作者
Migliorati, Julia M.
Liu, Sunna
Liu, Anna
Gogate, Anagha
Nair, Sreenidhi
Bahal, Raman
Rasmussen, Theodore P.
Manautou, Jose E.
Zhong, Xiao-bo
机构
[1] University of Connecticut, CT
[2] University of Connecticut, CT, Storrs
[3] Pharmacology, University of Connecticut, CT, Storrs
来源
FASEB JOURNAL | 2022年 / 36卷
关键词
D O I
10.1096/fasebj.2022.36.S1.R5892
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Absorption, distribution, metabolism, and excretion (ADME) are key biological processes for determination of a drug's pharmacokinetic parameters, which have direct impacts on therapeutic efficacy and adverse drug reactions (ADRs). Drug structures, formulations, and administration sites and routes cause different classes of drugs to have various ADME characteristics and consequent impacts upon efficacy and ADRs. For example, orally administered small molecule drugs are usually absorbed and distributed by uptake transporters, biotransformed by phase I/II drug-metabolizing enzymes, and excreted by efflux transporters. However, newly developed large molecule biological drugs, including antisense oligonucleotide (ASO) drugs, have substantially different ADME parameters. ASO drugs are single-stranded antisense nucleic acids with diverse modes of drug action that induce mRNA degradation, exon skipping, and ASO-protein interactions. ASOs have a great potential to treat certain human diseases that have not been treatable with small molecule drugs. The ADME behaviors of ASO drugs contribute to their unique set of ADRs and toxicity. To better understand their ADME features, ten FDA-approved ASO drugs were selected, including Fomivirsen, Pegaptanib, Nusinersen, Mipomersen, Inotersen, Defibrotide, Eteplirsen, Golodirsen, Viltolarsen, and Casimersen. A comprehensive meta-analysis was conducted on their formulation, dosage, sites of administration, local and systematic distribution, metabolism, degradation, and excretion. Membrane permeabilization and nucleotide degradation by endonucleases and exonucleases are major contributors to ADME features of the ASO drugs and these differ from the roles of transporters and metabolizing enzymes of small molecule drugs. The summarized information provides the most updated knowledge of ADME characteristics of these ASO drugs, leading to a better understanding of their therapeutic efficacy and potential ADRs and toxicity. Numerous knowledge gaps, particularly on cellular uptake and subcellular trafficking and distributions are identified and future perspective and directions are discussed. © FASEB.
引用
收藏
页数:1
相关论文
共 50 条
  • [1] Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma
    Ali, S
    Leonard, SA
    Kukoly, CA
    Metzger, WJ
    Wooles, WR
    McGinty, JF
    Tanaka, M
    Sandrasagra, A
    Nyce, JW
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (04) : 989 - 993
  • [2] FDA-Approved Oligonucleotide Therapies in 2017
    Stein, Cy A.
    Castanotto, Daniela
    MOLECULAR THERAPY, 2017, 25 (05) : 1069 - 1075
  • [3] Targeting nutrient metabolism with FDA-approved drugs for cancer chemoprevention: Drugs and mechanisms
    Xie, Yifei
    Yao, Ke
    Dong, Zigang
    Liu, Kangdong
    CANCER LETTERS, 2021, 510 : 1 - 12
  • [4] Safety of FDA-Approved drugs - Reply
    Friedman, MA
    Woodcock, J
    Lumpkin, MM
    Shuren, JE
    Hass, AE
    Thompson, LJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (24): : 2297 - 2298
  • [5] NONAPPROVED USES OF FDA-APPROVED DRUGS
    ANDERSON, BJ
    JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1970, 211 (10): : 1705 - &
  • [6] An analysis of FDA-approved drugs for oncology
    Kinch, Michael S.
    DRUG DISCOVERY TODAY, 2014, 19 (12) : 1831 - 1835
  • [7] Special Section on Pharmacokinetics and ADME of Biological Therapeutics-Minireview Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs
    Migliorati, Julia M.
    Liu, Sunna
    Liu, Anna
    Gogate, Anagha
    Nair, Sreenidhi
    Bahal, Raman
    Rasmussen, Theodore P.
    Manautou, Jose E.
    Zhong, Xiao-bo
    DRUG METABOLISM AND DISPOSITION, 2022, 50 (06) : 888 - 897
  • [8] Antisense oligonucleotides: absorption, distribution, metabolism, and excretion
    Shadid, Mohammad
    Badawi, Mohamed
    Abulrob, Abedelnasser
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (11) : 1281 - 1292
  • [9] A review on synthesis of FDA-approved antipsychotic drugs
    Rani, Anjali
    Aslam, Mohd
    Pandey, Garima
    Pant, Bhaskara Nand
    TETRAHEDRON, 2023, 138
  • [10] An analysis of FDA-approved drugs for pain and anesthesia
    Kinch, Michael S.
    DRUG DISCOVERY TODAY, 2015, 20 (01) : 3 - 6